Evolution of ProStrakan

2010:

- ProStrakan wins Innovation Award in Scottish PLC Awards

- Abstral filed for Canadian approval by partner, Paladin

2009: 

- Abstral filed for US approval

- ProStrakan partners with Endo for Fortigel (FORTESTA) in the US

- Notice of Allowance for US Patent for Sancuso received

- US Co-Promotion Agreement for Oncology Support Product, Gelclair

- Abstral Receives Marketing Approval in France and Spain

2008:

- Sancuso launched in US

- Sancuso receives US approval

- North American rights to Abstral acquired

- Abstral receives Swedish approval

- Abstral receives receives EU approval

- Fortigel (Tostran) successfully completes pivotal US trial

- Cellegesic (Rectogesic) successfully completes pivotal US trial

2007:

- Peter Allen takes over as chairman from founder, Harry Stratford

- US collaboration with NovaQuest announced

- Sancuso NDA filed in the US

- Cellegesic (Rectogesic) and Fortigel (Tostran) enter Phase III US trials

- Nordic sales joint venture with Orexo AB

- Tostran launched across Europe

- £50m debt facility secured

2006:

- Sale of Drug Discovery Unit (formerly ProSkelia)

- Zindaclin out-licensed to Crawford Healthcare

- Cellegy asset acquisition (Tostran and Rectogesic, USA)

- Collaboration with Novartis (bone)

- Collaboration with Amgen (renal)

2005:

- Rapinyl in-licensed

- Tostran launched (Tostrex, Sweden)

- Flotation on the LSE

- Rectogesic in-licensed (EU)

- APS Pharma acquired (Germany)

- Rectogesic launched

2004:

- Strakan / ProSkelia merged

- OTL Pharma acquired (Paris)

- Elfar and Devon Farmacéutica acquired (Spain)

- Tostran in-licensed (EU)

2001:

- Isotard in-licensed

- Adcal D3 in-licensed

1995:

- Strakan founded by Harry Stratford and Prof John Kanis